MUSCANO (CA 11991-18-1-

SEQUENCE LISTING

<110> CENTRO DE INMUNOLOGIA MOLECULAR

5	MATEO DE ACOSTA DEL RIO, Maria Cristina (Applicant only for United States of America) ROQUE NAVARRO, Lourdes Tatiana
	(Applicant only for United States of America) MORALES MORALES, Alejo
10	(Applicant only for United States of America) PEREZ RODRIGUEZ, Rolando
	(Applicant only for United States of America) AYALA AVILA, Marta
	(Applicant only for United States of America)
15	GAVILONDO COWLEY, Jorge Víctor
	(Applicant only for United States of America) DUEÑAS PORTO, Marta
	(Applicant only for United States of America) BELL GARCIA, Hanssel
20	(Applicant only for United States of America) RENGIFO CALZADO, Enrique
	(Applicant only for United States of America) IZNAGA ESCOBAR, Normando
	(Applicant only for United States of America)
25	RAMOS ZUZARTE, Mayra
	(Applicant only for United States of America)

30 <120> ANTIBODIES AND FV FRAGMENT RECOGNIZING ANTIGEN IOR C2.

<130> CIM

<140> PCT/CU00/00004

35 <141> 2000-11-16

<160> 14

40 <170> Patentin Ver. 2,0

<210> 1

<211>6

<212> PRT

45 <213> mammalian

<220>

<221> DOMAIN

<222> (1)..(6)

<223> CDR1 OF THE HEAVY CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT

```
<400> 1
     Ser Ala Tyr Asn Trp His
       1
                     5
 5
     <210>2
     <211>16
10
     <212> PRT
     <213> mammalian
     <220>
     <221> DOMAIN
15
     <222> (1)..(16)
     <223> CDR2 OF THE HEAVY CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT
     <400>2
     Tyr lle Ser Tyr Asn Gly Thr Thr Ser Tyr Asn Pro Ser Leu Lys Ser
20
                    5
                                    10
     <210>3
     <211>9
25
     <212> PRT
     <213> mammalian
                                               <220>
     <221> DOMAIN
     <222> (1)..(9)
                                                    <223> CDR3 OF THE HEAVY CHAIN
30
     RECOMBINANT ANTIBODY AND scFv FRAGMENT
     <400>3
     Asn Asp Glu Arg Ala Trp Phe Ala Tyr
35
       1
                     5
     <210>4
     <211>16
     <212> PRT
40
     <213> mammalian
                                               <220>
     <221> DOMAIN
     <222> (1)..(16)
     <223> CDR1 OF THE LIGHT CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT
45
     <400> 4
     Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn
                    5
                                      10
                                                       15
      1
```

```
43
The Carle of the Carle of the Carle
# C.
-
-
```

```
<210>5
            <211>7
            <212> PRT
            <213> mammalian
            <220>
            <221> DOMAIN
            <222> (1)..(7)
            <223> CDR2 OF THE LIGHT CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT
       10
            <400> 5
            Leu Val Ser Lys Leu Asp Ser
       15
<210>6
            <211>9
       20
            <212> PRT
            <213> mammalian
       25
            <220>
            <221> DOMAIN
            <222> (1)..(9)
            <223> CDR3 OF THE LIGHT CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT
       30
            <400>6
            Trp Gln Gly Thr His Phe Pro His Thr
                           5
       35
            <210>7
            <211>30
            <212> PRT
            <213> mammalian
       40
            <220>
            <221> DOMAIN
            <222> (1)..(30)
            <223> FR1 OF THE HEAVY CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
      45
            <400>7
            Asp Val Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gin
                                            10
                           5
      50
```

Thr Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr 20 25 30

```
<210>8
 5
     <211> 14
     <212> PRT
     <213> mammalian
     <220>
10
     <221> DOMAIN
     <222> (1)..(14)
     <223> FR2 OF THE HEAVY CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
     <400>8
15
     Trp lie Arg Gin Phe Pro Gly Lys Gly Leu Glu Trp Met Gly
                    5
       1
     <210>9
     <211> 32
20
     <212> PRT
     <213> mammalian
     <220>
     <221> DOMAIN
25
     <222> (1)..(32)
     <223> FR3 OF THE HEAVY CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
     <400>9
     Arg lie Ser lie Thr Arg Asp Thr Ser Lys Asn Gin Phe Phe Leu Gin
30
                   5
                                    10
     Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
                                  25
35
     <210> 10
     <211> 11
     <212> PRT
     <213> mammalian
40
     <220>
     <221> DOMAIN
     <222> (1)..(11)
     <223> FR4 OF THE HEAVY CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
45
     <400> 10
     Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
```

10

5

50

```
<220>
             <221> DOMAIN
             <222> (1)..(23)
        10
             <223> FR1 OF THE LIGHT CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
             <400> 11
             Asp Trp Trp Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Leu Gly
        15
Gln Pro Ala Ser lie Ser Cys
                       20
        20
             <210> 12
             <211> 15
             <212> PRT
THE THE THE
             <213> mammalian
        25
             <220>
             <221> DOMAIN
             <222> (1)..(15)
             <223> FR2 OF THE LIGHT CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
30
             <400> 12
             Trp Leu Leu Gin Arg Pro Gly Gin Ser Pro Arg Arg Leu lle Tyr
                                              10
        35
             <210> 13
             <211>32
             <212> PRT
             <213> mammalian
       40
             <220>
             <221> DOMAIN
```

<210> 11 <211>23 <212> PRT

<213> mammalian

<222> (1)..(32)

<400> 13

50

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ala

<223> FR3 OF THE LIGHT CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT

Leu Lys Ile Arg Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys 20 25 30

```
    5
        <210> 14
        <211> 17
        <212> PRT
        <213> mammalian

    <220>
        <221> DOMAIN
        <222> (1)..(17)
        <223> FR4 OF THE LIGHT CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT

    <400> 14
        Phe Gly Gly Gly Thr Lys Leu Glu lle Lys Arg Lys Ser Thr Leu Thr
        1
        5
        10
        15
```

Gly

30

25

35

40